v3.26.1
Segment Information (Tables)
6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Schedule of reportable segment

Three months ended

Six months ended

June 30, 

June 30, 

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

Product revenue, net

$

182

$

120

$

388

$

288

Less:

Cost of goods sold

$

22

$

107

$

305

$

121

Research and development costs:

Personnel and related costs

$

1,404

$

1,585

$

2,869

$

3,267

Non-cash stock-based compensation

51

648

130

134

Professional fees

501

1,007

1,043

1,786

Clinical trials expense

334

6,119

717

8,137

Chemical, manufacturing and controls cost

632

535

823

710

Other expenses

242

362

537

776

Total research and development costs

$

3,164

$

10,256

$

6,119

$

14,810

Commercial costs:

Personnel and related costs

78

84

156

163

Non-cash stock-based compensation

-

Professional fees

74

138

92

176

Commercial and marketing

52

38

146

207

Travel related expenses

3

12

6

21

Other expenses

10

(45)

24

(133)

Total commercial costs

$

217

$

227

$

424

$

434

Selling, general and administrative costs:

 

 

 

Personnel and related costs

1,104

946

$

2,160

$

1,939

Non-cash stock-based compensation

307

908

 

663

1,602

Professional fees

4,794

2,572

 

9,312

5,406

Travel related expenses

38

132

110

248

Other expenses

729

824

 

1,711

1,679

Total selling, general and administrative costs

$

6,972

$

5,382

$

13,956

$

10,874

Total operating expenses

$

10,375

$

15,972

$

20,804

$

26,239

Other (income) expense

 

 

 

  ​

 

  ​

Interest expense

 

4,257

 

4,222

 

8,455

 

8,215

Interest income

(131)

(230)

(342)

(509)

Other (income) expense, net

394

(657)

(1,125)

(7,216)

Segment net loss

$

(14,713)

$

(19,187)

$

(27,404)

$

(26,441)

Adjustments and reconciling items

Consolidated Net Loss

$

(14,713)

$

(19,187)

$

(27,404)

$

(26,441)